Skip to main content
PYPD
NASDAQ Industrial Applications And Services

PolyPid Initiates D-PLEX₁₀₀ NDA Submission to FDA for Surgical Site Infection Prevention

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$4.16
Mkt Cap
$80.34M
52W Low
$2.3
52W High
$5.12
52W Position info
81% above low
Off High info
19% below high
Rel. Volume info
1.1× avg
Market data snapshot near publication time

PYPD sits 81% above its 52-week low of $2.3.

Summary

PolyPid Ltd. has begun its New Drug Application (NDA) submission to the FDA for D-PLEX₁₀₀, a key step towards commercialization for preventing surgical site infections, with completion expected in Q2 2026.


Key Events · Product Development and Regulatory · PYPD

  • NDA Submission Initiated

    PolyPid has started the New Drug Application (NDA) submission to the U.S. Food and Drug Administration (FDA) for D-PLEX₁₀₀, aimed at preventing surgical site infections (SSIs) in colorectal surgery patients.

  • Rolling Review Under Fast Track

    The NDA is being submitted under the FDA's Fast Track designation, allowing for a rolling review process. The Chemistry, Manufacturing and Controls (CMC) and nonclinical sections have been submitted, with the clinical section expected in Q2 2026.

  • Follows Positive Phase 3 Results

    This submission follows positive results from the Phase 3 SHIELD II trial, where D-PLEX₁₀₀ achieved a statistically significant 60% relative risk reduction in SSI incidence.

  • Commercialization Partnership Discussions

    The company is actively advancing discussions for a U.S. commercialization partnership for D-PLEX₁₀₀.


Analysis · PYPD · Industrial Applications And Services

PolyPid Ltd. has commenced the New Drug Application (NDA) submission for its lead product candidate, D-PLEX₁₀₀, to the FDA. This is a critical regulatory milestone for the company, moving its primary asset closer to potential commercialization. The Fast Track designation allows for a rolling review, which could expedite the approval process. Given the positive Phase 3 SHIELD II trial results and Breakthrough Therapy Designation, this submission significantly de-risks the product's path to market. For a company of PolyPid's size, successful NDA submission and potential approval are transformative events, further bolstered by ongoing discussions for a U.S. commercialization partnership.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, PYPD was trading at $4.16 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $80.3M. The 52-week trading range was $2.30 to $5.12. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

PYPD - Latest Insights

PYPD
Nov 12, 2026, 8:39 AM EST
Filing Type: 6-K
Importance Score:
7
Price at Filing: $6.97
Real-time Price: $6.12 info
Change: -$0.850 (-12%) info
Market Cap: $129.289M info
PYPD
Nov 11, 2026, 9:31 AM EST
Source: Reuters
Importance Score:
7
Price at Filing: $6.22
Real-time Price: $6.12 info
Change: -$0.0991 (-2%) info
Market Cap: $129.289M info
PYPD
Oct 28, 2026, 8:03 AM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $5.75
Real-time Price: $6.12 info
Change: +$0.370 (+6%) info
Market Cap: $129.289M info
PYPD
Oct 01, 2026, 9:20 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $5.30
Real-time Price: $6.12 info
Change: +$0.820 (+15%) info
Market Cap: $129.289M info
PYPD
Oct 01, 2026, 8:56 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $5.27
Real-time Price: $6.12 info
Change: +$0.850 (+16%) info
Market Cap: $129.289M info